A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)

What is the purpose of this trial?

The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in adult participants with recurrent or metastatic cutaneous Squamous Cell Carcinoma (R/M cSCC) that is not amenable to surgery and/or radiation and/or systemic therapies.



Merck Sharp & Dohme

Start Date: 01/03/2018

End Date: 11/25/2020

Last Updated: 01/25/2019

Study HIC#: 2000021310

Get Involved

For more information about this study, contact:
Elzbieta Nowacki
+1 203-737-7981
elzbieta.nowacki@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image